Medicago announces research collaboration for the development of a VLP vaccine candidate for the prevention of Ebola with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)

May 26, 2011

QUEBEC CITY, May 26, 2011 /PRNewswire/ – Medicago Inc. (TSX: MDG), a
biotechnology company focused on developing highly effective and
competitive vaccines based on proprietary manufacturing technologies
and Virus-Like Particles (VLPs), today announced that it has entered
into a research collaboration agreement with the U.S. Army Medical
Research Institute of Infectious Diseases (USAMRIID) for the
development of a plant-based VLP vaccine candidate for the prevention
of Ebola. Ebola is a very serious hemorrhagic fever virus for which no
licensed treatment or vaccine exists.

“We are currently working on several other important infectious disease
targets outside of influenza,” said Louis Vezina, Chief Scientific
Officer of Medicago. “Our expertise in the development of VLP vaccines
using our transient expression system, coupled with USAMRIID’s
experience and knowledge creates an ideal combination for the rapid
development of a new generation of efficacious and competitive VLP

Medicago’s VLP plant-based technology is being utilized in multiple
preclinical and clinical trials. Medicago remains on track to report
final phase II clinical trial results for its H5N1 vaccine candidate
this quarter along with U.S. phase I clinical trial results for its
seasonal flu vaccine candidate.


USAMRIID, located at Fort Detrick, Maryland, is the lead medical
research laboratory for the U.S. Department of Defense’s Biological
Defense Research Program, and plays a key role in national defense and
in infectious disease research. The Institute conducts basic and
applied research on biological threats resulting in medical solutions
(such as vaccines, drugs and diagnostics) to protect the warfighter.
While USAMRIID’s primary mission is focused on the military, its
research often has applications that benefit society as a whole.
USAMRIID is a subordinate laboratory of the U.S. Army Medical Research
and Materiel Command. For more information, visit www.usamriid.army.mil .

About Medicago

Medicago is a clinical-stage biotechnology company, developing effective
and competitive vaccines based on proprietary Virus-Like Particles
(VLP) and manufacturing technologies. Medicago is developing VLP
vaccines to protect against pandemic and seasonal influenza, using a
transient expression system which produces recombinant vaccine antigens
in non-transgenic plants. This technology has potential to offer
advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification
and reception of the genetic sequence. This production time frame has
the potential to allow vaccination of the population before the first
wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.

Forward Looking Statements

This news release includes certain forward-looking statements that are
based upon current expectations, which involve risks and uncertainties
associated with Medicago’s business and the environment in which the
business operates. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions “anticipate”, “believe”,
“plan”, “estimate”, “expect”, “intend”, and similar expressions to the
extent they relate to Medicago or its management. The forward-looking
statements are not historical facts, but reflect Medicago’s current
expectations regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results or events to differ materially from current
expectations, including the matters discussed under “Risks Factors and
Uncertainties” in Medicago’s Annual Information Form filed on March 24,
2010 with the regulatory authorities. Medicago assumes no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those reflected in the forward-looking

[The information contained in this press release does not necessarily
reflect the position or the policy of the Government and no official
endorsement should be inferred.]

SOURCE Medicago Inc.

Source: newswire

comments powered by Disqus